IP Library Granted Patent US 7,704,953
Granted Patent B2
US 7,704,953 · App. 11/627,863 · Granted Apr 27, 2010

Phage displayed cell binding peptides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,704,953
App. No.
11/627,863
Granted
Apr 27, 2010
Kind
B2
Abstract

The present disclosure relates to the construction, expression, and selection of genes that encode novel Trp cage polypeptides with desirable cell and/or tissue binding properties, as well as the novel Trp cage polypeptides themselves. A polypeptide of this disclosure may contain all or part of amino acid sequence AAADX 1 YX 2 QWLX 3 X 4 X 5 GPX 6 SGRPPPX 7 (SEQ ID NO: 4), wherein X n represents an amino acid found in position n, the polypeptide comprising a tryptophan cage (Trp cage).

Claims (17)

1. A method for delivering a drug, compound or biologically active agent to a lung tissue of a subject, the method comprising: complexing or conjugating the drug, compound or biologically active agent with a polypeptide comprising the amino acid sequence of SEQ ID NO: 543 or SEQ ID NO: 551 thereby forming a complex or conjugate, and administering the complex or conjugate to the lung tissue of the subject.

2. The method of claim 1 , wherein the drug, compound or biologically active agent is an siRNA molecule.

3. The method of claim 1 , wherein the polypeptide binds lung tissue.

4. The method of claim 1 , wherein the polypeptide binds a human bronchial epithelial cell.

5. The method of claim 1 , wherein the complex or conjugate is administered intravenously.

6. The method of claim 1 , wherein the complex or conjugate is administered by injection.

7. A method for delivering a biologically active agent to a lung cell, the method comprising: complexing or conjugating the biologically active agent with a polypeptide comprising the amino acid sequence of SEQ ID NO: 543 or SEQ ID NO: 551, thereby forming a complex or conjugate, and administering the complex or conjugate to the lung cell.

8. The method of claim 7 , wherein the biologically active agent is an siRNA molecule.

9. The method of claim 7 , wherein the polypeptide binds the lung cell.

10. The method of claim 7 , wherein the polypeptide binds a bronchial epithelial cell.

11. The method of claim 7 , wherein the complex or conjugate is administered intravenously or by injection.

12. A method for preparing an RNAi agent for targeting to lung tissue, the method comprising:

providing an RNAi agent; and

contacting the RNAi agent with a polypeptide comprising the amino acid sequence of SEQ ID NO: 543 or SEQ ID NO: ID NO: 551, thereby forming a complex or conjugate of the RNAi agent.

13. The method of claim 12 , wherein the RNAi agent is an siRNA molecule.

14. The method of claim 12 , wherein the polypeptide binds the lung tissue.

15. The method of claim 12 , wherein the polypeptide binds a bronchial epithelial cell.